A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory to Janus Kinase (JAK)-Inhibitor treatment.
Epistemonikos ID: 11c7fbbb36a9ce2770c6a4f2116f541233aa0870
First added on: May 07, 2024